IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable.
Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Change from offer price to today
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:PBLS
Key valuation ratios and metrics
Balance sheet strength and liquidity
Historical financial performance
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | $29.04 | $30.19 | $27.44 | $29.19 | $29.19 | +0.15 | 557,000 |
| 2026-06-26 | $26.05 | $29.10 | $26.05 | $28.80 | $28.80 | +2.75 | 581,300 |
| 2026-06-25 | $27.32 | $27.99 | $25.70 | $26.36 | $26.36 | -0.96 | 1,043,400 |
| 2026-06-24 | $27.46 | $28.42 | $26.58 | $27.32 | $27.32 | -0.14 | 599,800 |
| 2026-06-23 | $26.51 | $28.28 | $26.23 | $27.51 | $27.51 | +1.00 | 627,900 |
| 2026-06-22 | $26.00 | $28.06 | $25.56 | $27.54 | $27.54 | +1.54 | 830,800 |
| 2026-06-18 | $25.98 | $27.00 | $25.35 | $25.85 | $25.85 | -0.13 | 685,100 |
| 2026-06-17 | $30.00 | $30.22 | $25.98 | $26.03 | $26.03 | -3.97 | 1,929,200 |
| 2026-06-16 | $25.26 | $26.72 | $24.91 | $26.59 | $26.59 | +1.33 | 3,384,300 |
| 2026-06-15 | $26.80 | $28.08 | $24.51 | $25.01 | $25.01 | -1.79 | 1,280,300 |
| 2026-06-12 | $29.86 | $32.47 | $26.88 | $27.26 | $27.26 | -2.60 | 1,035,500 |
| 2026-06-11 | $30.00 | $34.47 | $29.65 | $30.31 | $30.31 | +0.31 | 1,600,200 |
| 2026-06-10 | $33.35 | $34.02 | $26.61 | $31.60 | $31.60 | -1.75 | 5,496,700 |
| 2026-06-09 | $20.00 | $20.00 | $20.00 | $20.00 | $20.00 | 0.00 | 0 |
| 2026-06-08 | $20.00 | $20.00 | $20.00 | $20.00 | $20.00 | 0.00 | 0 |
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Jun 18, 2026 | Filing |
| 8-K | Jun 11, 2026 | Current Report |
| S-8 | Jun 10, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Jun 10, 2026 | Prospectus |
| FWP | Jun 10, 2026 | Free Writing Prospectus |
| EFFECT | Jun 9, 2026 | Notice of Effectiveness |
| S-1MEF | Jun 9, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Jun 9, 2026 | Certification by an exchange approving securities for listing |
| S-1/A | Jun 9, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| 8-A12B | Jun 5, 2026 | Registration of securities |
Contact and headquarters details
Key executives and officers
Mathai Mammen, M.D., Ph.D.
Chairman, Chief Executive Officer and President
Fawzi Benzaghou, M.D.
Chief Medical Officer
Helen Ho, Ph.D.
Chief Business and Strategy Officer
Thomas Kotarakos
Chief Financial Officer
Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Teresa Jurgensen, J.D.
General Counsel
Alexis Borisy
Director
Edward Fitzgerald
Director
Rick Klausner, M.D.
Director
Alan M. Sebulsky
Director

USD · NASDAQ:PBLS
Issue Size
$670.00M
Price Range
$17.00 - $19.00
Shares
127.34M o/s · 33.5M offered
Listing Price
$20.00
Listing date
Jun 10, 2026
Sector
Healthcare